全文获取类型
收费全文 | 8589篇 |
免费 | 530篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 208篇 |
妇产科学 | 230篇 |
基础医学 | 1242篇 |
口腔科学 | 78篇 |
临床医学 | 697篇 |
内科学 | 2146篇 |
皮肤病学 | 283篇 |
神经病学 | 772篇 |
特种医学 | 296篇 |
外科学 | 835篇 |
综合类 | 34篇 |
预防医学 | 537篇 |
眼科学 | 146篇 |
药学 | 662篇 |
中国医学 | 21篇 |
肿瘤学 | 956篇 |
出版年
2024年 | 8篇 |
2023年 | 67篇 |
2022年 | 138篇 |
2021年 | 288篇 |
2020年 | 159篇 |
2019年 | 211篇 |
2018年 | 219篇 |
2017年 | 186篇 |
2016年 | 243篇 |
2015年 | 290篇 |
2014年 | 316篇 |
2013年 | 414篇 |
2012年 | 673篇 |
2011年 | 704篇 |
2010年 | 349篇 |
2009年 | 349篇 |
2008年 | 561篇 |
2007年 | 544篇 |
2006年 | 562篇 |
2005年 | 575篇 |
2004年 | 500篇 |
2003年 | 445篇 |
2002年 | 366篇 |
2001年 | 91篇 |
2000年 | 86篇 |
1999年 | 100篇 |
1998年 | 78篇 |
1997年 | 62篇 |
1996年 | 57篇 |
1995年 | 48篇 |
1994年 | 38篇 |
1993年 | 30篇 |
1992年 | 44篇 |
1991年 | 44篇 |
1990年 | 42篇 |
1989年 | 40篇 |
1988年 | 35篇 |
1987年 | 28篇 |
1986年 | 18篇 |
1985年 | 28篇 |
1984年 | 21篇 |
1983年 | 15篇 |
1982年 | 7篇 |
1980年 | 14篇 |
1979年 | 18篇 |
1978年 | 9篇 |
1975年 | 7篇 |
1973年 | 10篇 |
1971年 | 6篇 |
1966年 | 7篇 |
排序方式: 共有9192条查询结果,搜索用时 31 毫秒
991.
Mario Di Gioacchino Fabio Di Stefano Enrico Cavallucci Nicola Verna Stefania Ramondo Franco Paolini Riccardo Caruso Cosima Schiavone Silvio Masci Bartolomeo Santucci Roberto Paganelli Pio Conti 《Allergy and asthma proceedings》2003,24(4):285-290
This study evaluates the effectiveness and safety of cyclosporine (CsA) in the treatment of patients with chronic idiopathic urticaria with a positive autologous serum skin test (ASST), who fail to respond to conventional therapy, and requiring long-term oral steroid treatment. In a double-blind study, 40 adults were assigned randomly to receive CsA (5 mg/kg per day for 8 weeks and then 4 mg/kg per day for 8 weeks) or cetirizine (10 mg/day) and then they were followed up for 9 months. After 2 weeks, the study was opened because 16 patients (40%) had daily severe relapses requiring systemic steroids treatment. All of these patients had been receiving antihistamines and, therefore, all patients also were assigned to the CsA treatment regimen (5 mg/kg per day for 8 weeks and then 4 mg/kg per day for 8 weeks). The ASST and clinical severity score were evaluated before and after treatment. All of the 40 patients completed the 16-week CsA course without dropping out because of relevant side effects. In three patients, CsA was reduced by 0.5 mg/kg per day after the 1st month of treatment for a mild and reversible increase in serum creatinine. During CsA treatment, 20 patients had relapses resolving spontaneously (8 patients) or with antihistamines (12 patients). During the 9-month follow-up period, 22 patients had relapses resolving spontaneously (10 patients) or with antihistamines (12 patients). Only two patients failed to complete the study because of severe symptoms occurring after 4 and 7 days of follow-up and requiring long-term steroid treatment. After 9 months of follow-up, 16 patients were still in full remission. The clinical severity score of chronic idiopathic urticaria dropped significantly by the end of the 4th month of treatment (p = 0.002) as well as by the completion of follow-up (p = 0.007). The ASST was negative in 13 patients and positive in 3 of 16 patients, with total remission of symptoms. Significant score reduction also was observed in patients experiencing relapses that resolved spontaneously (p = 0.005) or with antihistamines (p = 0.03). These results show the long-term efficacy and tolerability of CsA in patients with severe chronic idiopathic urticaria, unresponsive to conventional treatments. 相似文献
992.
993.
Giorgina?Barbara?PiccoliEmail author Marta?Nazha Irene?Capizzi Federica?Neve?Vigotti Stefania?Scognamiglio Valentina?Consiglio Elena?Mongilardi Marilisa?Bilocati Paolo?Avagnina Elisabetta?Versino 《BMC nephrology》2016,17(1):197
Background
There is no single, gold-standard, low-protein diet (LPD) for CKD patients; the best compliance is probably obtained by personalization. This study tests the hypothesis that a multiple choice diet network allows patients to attain a good compliance level, and that, in an open-choice system, overall results are not dependent upon the specific diet, but upon the clinical characteristics of the patients.Methods
Observational study: Three LPD options were offered to all patients with severe or rapidly progressive CKD: vegan diets supplemented with alpha-ketoacids and essential aminoacids; protein-free food in substitution of normal bread and pasta; other (traditional, vegan non supplemented and tailored). Dialysis-free follow-up and survival were analyzed by Kaplan Meier curves according to diet, comorbidity and age.Compliance and metabolic control were estimated in 147 subjects on diet at March 2015, with recent complete data, prescribed protein intake 0.6 g/Kg/day. Protein intake was assessed by Maroni Mitch formula.Results
Four hundreds and forty nine patients followed a LPD in December, 2007- March, 2015 (90% moderately restricted LPDs, 0.6 g/Kg/day of protein, 10% at lower targets); age (median 70 (19–97)) and comorbidity (Charlson index: 7) characterized our population as being in line with the usual CKD European population. Median e-GFR at start of the diet was 20 mL/min, 33.2% of the patients were diabetics. Baseline data differ significantly across diets: protein-free schemas are preferred by older, high-comorbidity patients (median age 76 years, Charlson index 8, GFR 20.5 mL/min, Proteinuria: 0.3 g/day), supplemented vegan diets by younger patients with lower GFR and higher proteinuria (median age 65 years, Charlson index 6, GFR 18.9 mL/min; Proteinuria: 1.2 g/day); other diets are chosen by an intermediate population (median age 71 years, Charlson index 6; GFR 22.5 mL/min; Proteinuria: 0.9 g/day); (p?<0.001 for age, Charlson index, proteinuria, GFR). Adherence was good, only 1.1% of the patients were lost to follow-up and protein intake was at target in most of the cases with no differences among LPDs (protein intake: 0.47 (0.26–0.86) g/Kg/day). After adjustment for confounders, and/or selection of similar populations, no difference in mortality or dialysis start was observed on the different LPDs. Below the threshold of e-GFR 15 mL/min, 50% of the patients remain dialysis free for at least two years.Conclusion
A multiple choice LPD system may allow reaching good adherence, without competition among diets, and with promising results in terms of dialysis-free follow-up. The advantages with respect to a non-customized approach deserve confirmation in further comparative studies or RCTs.994.
Death of Bystander Cells by a Novel Pathway Involving Early Mitochondrial Damage in Human Immunodeficiency Virus-Related Lymphadenopathy 总被引:3,自引:0,他引:3
995.
Fiore LD Ezekowitz MD Brophy MT Lu D Sacco J Peduzzi P;Combination Hemotherapy Mortality Prevention 《Circulation》2002,105(5):557-563
BACKGROUND: Both aspirin and warfarin when used alone are effective in the secondary prevention of vascular events and death after acute myocardial infarction. We tested the hypothesis that aspirin and warfarin therapy, when combined, would be more effective than aspirin monotherapy. Methods and Results- We conducted a randomized open-label study to compare the efficacy of warfarin (target international normalized ratio 1.5 to 2.5 IU) plus aspirin (81 mg daily) with the efficacy of aspirin monotherapy (162 mg daily) in reducing the total mortality in 5059 patients enrolled within 14 days of infarction and followed for a median of 2.7 years. Secondary end points included recurrent myocardial infarction, stroke, and major hemorrhage. Four hundred thirty-eight (17.3%) of 2537 patients assigned to the aspirin group and 444 (17.6%) of 2522 patients assigned to the combination group died (log-rank P=0.76). Recurrent myocardial infarction occurred in 333 patients (13.1%) taking aspirin and in 336 patients (13.3%) taking combination therapy (log-rank P=0.78). Stroke occurred in 89 patients (3.5%) taking aspirin and in 79 patients (3.1%) taking combination therapy (log-rank P=0.52). Major bleeding occurred more frequently in the combination therapy group than in the aspirin group (1.28 versus 0.72 events per 100 person years of follow-up, respectively; P<0.001). There were 14 individuals with intracranial bleeds in both the aspirin and combination therapy groups. CONCLUSIONS: In post-myocardial infarction patients, warfarin therapy (at a mean international normalized ratio of 1.8) combined with low-dose aspirin did not provide a clinical benefit beyond that achievable with aspirin monotherapy. 相似文献
996.
997.
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome 总被引:13,自引:0,他引:13
Farci P Strazzera R Alter HJ Farci S Degioannis D Coiana A Peddis G Usai F Serra G Chessa L Diaz G Balestrieri A Purcell RH 《Proceedings of the National Academy of Sciences of the United States of America》2002,99(5):3081-3086
Despite recent treatment advances, the majority of patients with chronic hepatitis C fail to respond to antiviral therapy. Although the genetic basis for this resistance is unknown, accumulated evidence suggests that changes in the heterogeneous viral population (quasispecies) may be an important determinant of viral persistence and response to therapy. Sequences within hepatitis C virus (HCV) envelope 1 and envelope 2 genes, inclusive of the hypervariable region 1, were analyzed in parallel with the level of viral replication in serial serum samples obtained from 23 patients who exhibited different patterns of response to therapy and from untreated controls. Our study provides evidence that although the viral diversity before treatment does not predict the response to treatment, the early emergence and dominance of a single viral variant distinguishes patients who will have a sustained therapeutic response from those who subsequently will experience a breakthrough or relapse. A dramatic reduction in genetic diversity leading to an increasingly homogeneous viral population was a consistent feature associated with viral clearance in sustained responders and was independent of HCV genotype. The persistence of variants present before treatment in patients who fail to respond or who experience a breakthrough during therapy strongly suggests the preexistence of viral strains with inherent resistance to IFN. Thus, the study of the evolution of the HCV quasispecies provides prognostic information as early as the first 2 weeks after starting therapy and opens perspectives for elucidating the mechanisms of treatment failure in chronic hepatitis C. 相似文献
998.
999.
1000.
Mermans JF Tuinder S von Meyenfeldt MF van der Hulst RR 《Undersea & hyperbaric medicine》2012,39(3):719-723
The rate of complications in immediate breast reconstruction is in 15% to 20% due to partial loss of the mastectomy skin flaps. In the case of skin necrosis or ischemia, a therapy that reduces skin loss could be of additional benefit. Hyperbaric oxygen has been used to treat compromised flaps and grafts, an indication recognized and reimbursed according to the Undersea and Hyperbaric Medical Society (UHMS). So far, hyperbaric oxygen has not been previously reported as therapy for full-thickness breast skin flap necrosis on patients with a direct reconstruction with silicone implants after a skin-sparing mastectomy. This report presents such a case, in which a 52-year-old woman carrier of the BRCA2 mutation gene was successfully treated with hyperbaric oxygen therapy. 相似文献